Eli Lilly (LLY) director acquires 18.336 shares via fee deferral
Eli Lilly (LLY) director reported a routine equity accrual.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Eli Lilly (LLY) director reported a routine equity accrual. On 10/20/2025, the director acquired 18.336 shares of common stock at $808.96 per share, recorded as an “A” (acquisition). Following this transaction, the director beneficially owns 16,474.296 shares, held directly.
The filing notes these shares were deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in common shares after the director’s separation from service.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock | 18.336 | $808.96 | $15K |
Footnotes (1)
- F1. At the election of the reporting person, the shares acquired pursuant to this filing have been deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person's separation from service.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Eli Lilly (LLY) report in this Form 4?
What was the nature of the acquisition for LLY’s director?
When will the deferred stock units be settled for LLY’s director?
What was the transaction code in the Form 4 for LLY?
What is the insider’s relationship to Eli Lilly (LLY)?
AI-generated analysis. How Rhea-AI works. Not financial advice.